Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyo-Suk | - |
dc.contributor.author | Yoo, Byung Chul | - |
dc.contributor.author | Lee, Kwan Sik | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Um, Soon-Ho | - |
dc.contributor.author | Ryu, Soo Hyung | - |
dc.contributor.author | Lee, Young-Suk | - |
dc.contributor.author | Kim, Young Soo | - |
dc.contributor.author | Yoo, Kwon | - |
dc.contributor.author | Han, Joon-Yeol | - |
dc.contributor.author | Hwang, Jae Seok | - |
dc.contributor.author | Kim, Tae-Hun | - |
dc.contributor.author | Yang, Jin-Mo | - |
dc.contributor.author | Lee, Heon-Ju | - |
dc.contributor.author | Chon, Chae Yoon | - |
dc.contributor.author | Cho, Mong | - |
dc.contributor.author | Han, Byung Hoon | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Chung, Young-Hwa | - |
dc.contributor.author | Cho, Se-Hyun | - |
dc.contributor.author | Koh, Kwang Cheol | - |
dc.contributor.author | Kim, Byung-Ik | - |
dc.contributor.author | Kim, Haak Cheoul | - |
dc.contributor.author | Paik, Seung Woon | - |
dc.contributor.author | Lee, Myung-Seok | - |
dc.contributor.author | Yoo, Hee-Won | - |
dc.contributor.author | Han, Cheol Ju | - |
dc.date.accessioned | 2021-09-07T14:25:02Z | - |
dc.date.available | 2021-09-07T14:25:02Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-03 | - |
dc.identifier.issn | 0944-1174 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112892 | - |
dc.description.abstract | This study was conducted to evaluate the durability of clevudine-induced viral response after the withdrawal of treatment. Patients who showed a complete response [alanine aminotransferase (ALT) normalization and hepatitis B virus (HBV) DNA < 4,700 copies/mL for hepatitis B envelope antigen (HBeAg)-negative patients; ALT normalization, HBV DNA < 4,700 copies/mL, and HBeAg seroconversion for HBeAg-positive patients] in the previous clevudine phase III trials were followed for an additional 96 weeks without any treatment for hepatitis B. Of the 63 patients in the study cohort, 73% and 35% of the patients had HBV DNA < 141,500 and < 4,700 copies/mL, respectively, and 75% of the patients had normal ALT at the end of follow-up. HBeAg seroconversion was maintained in 81% of the patients and hepatitis B surface antigen (HBsAg) loss occurred in 3 patients. Continued HBsAg titer decrease (-0.5 log IU/mL) was observed in the sustained viral responders, suggesting the reduction of covalently closed circular DNA in hepatocytes. The clevudine-induced viral response was durable in the majority of patients for 2 years after the withdrawal of treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER JAPAN KK | - |
dc.subject | CHRONIC HEPATITIS-B | - |
dc.subject | E-ANTIGEN SEROCONVERSION | - |
dc.subject | LAMIVUDINE THERAPY | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | ANTIVIRAL ACTIVITY | - |
dc.subject | VIRUS-INFECTION | - |
dc.subject | L-FMAU | - |
dc.subject | DNA | - |
dc.subject | TELBIVUDINE | - |
dc.subject | SUPPRESSION | - |
dc.title | Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Um, Soon-Ho | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.1007/s00535-010-0354-x | - |
dc.identifier.scopusid | 2-s2.0-79954420265 | - |
dc.identifier.wosid | 000289003700015 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY, v.46, no.3, pp.410 - 414 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 46 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 410 | - |
dc.citation.endPage | 414 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-B | - |
dc.subject.keywordPlus | E-ANTIGEN SEROCONVERSION | - |
dc.subject.keywordPlus | LAMIVUDINE THERAPY | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | ANTIVIRAL ACTIVITY | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | L-FMAU | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | TELBIVUDINE | - |
dc.subject.keywordPlus | SUPPRESSION | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | HBV DNA | - |
dc.subject.keywordAuthor | ccc-DNA | - |
dc.subject.keywordAuthor | HBeAg seroconversion | - |
dc.subject.keywordAuthor | HBsAg loss | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.